Search

Your search keyword '"Bernstein PR"' showing total 2 results
Start Over Author "Bernstein PR" Topic antineoplastic agents
2 results on '"Bernstein PR"'

1. Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization.

Author

Karche NP, Bhonde M, Sinha N, Jana G, Kukreja G, Kurhade SP, Jagdale AR, Tilekar AR, Hajare AK, Jadhav GR, Gupta NR, Limaye R, Khedkar N, Thube BR, Shaikh JS, Rao Irlapati N, Phukan S, Gole G, Bommakanti A, Khanwalkar H, Pawar Y, Kale R, Kumar R, Gupta R, Praveen Kumar VR, Wahid S, Francis A, Bhat T, Kamble N, Patil V, Nigade PB, Modi D, Pawar S, Naidu S, Volam H, Pagdala V, Mallurwar S, Goyal H, Bora P, Ahirrao P, Singh M, Kamalakannan P, Naik KR, Kumar P, Powar RG, Shankar RB, Bernstein PR, Gundu J, Nemmani K, Narasimham L, George KS, Sharma S, Bakhle D, Kamboj RK, and Palle VP

Subjects
Animals, Antineoplastic Agents metabolism, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Binding Sites, Cell Line, Tumor, Cell Survival drug effects, Half-Life, Humans, Mice, Mice, Inbred BALB C, Molecular Docking Simulation, Naphthyridines metabolism, Neoplasms drug therapy, Neoplasms pathology, Poly (ADP-Ribose) Polymerase-1 metabolism, Poly(ADP-ribose) Polymerase Inhibitors metabolism, Poly(ADP-ribose) Polymerase Inhibitors pharmacology, Poly(ADP-ribose) Polymerase Inhibitors therapeutic use, Quinolones metabolism, Structure-Activity Relationship, Transplantation, Heterologous, Antineoplastic Agents chemistry, Naphthyridines chemistry, Poly (ADP-Ribose) Polymerase-1 antagonists & inhibitors, Poly(ADP-ribose) Polymerase Inhibitors chemistry, Quinolones chemistry
Abstract

The exploitation of GLU988 and LYS903 residues in PARP1 as targets to design isoquinolinone (I & II) and naphthyridinone (III) analogues is described. Compounds of structure I have good biochemical and cellular potency but suffered from inferior PK. Constraining the linear propylene linker of structure I into a cyclopentene ring (II) offered improved PK parameters, while maintaining potency for PARP1. Finally, to avoid potential issues that may arise from the presence of an anilinic moiety, the nitrogen substituent on the isoquinolinone ring was incorporated as part of the bicyclic ring. This afforded a naphthyridinone scaffold, as shown in structure III. Further optimization of naphthyridinone series led to identification of a novel and highly potent PARP1 inhibitor 34, which was further characterized as preclinical candidate molecule. Compound 34 is orally bioavailable and displayed favorable pharmacokinetic (PK) properties. Compound 34 demonstrated remarkable antitumor efficacy both as a single-agent as well as in combination with chemotherapeutic agents in the BRCA1 mutant MDA-MB-436 breast cancer xenograft model. Additionally, compound 34 also potentiated the effect of agents such as temozolomide in breast cancer, pancreatic cancer and Ewing's sarcoma models., (Copyright © 2020 Elsevier Ltd. All rights reserved.)

Published
2020
Full Text
View/download PDF

2. Discovery of a Potent and Selective PI3Kδ Inhibitor ( S )-2,4-Diamino-6-((1-(7-fluoro-1-(4-fluorophenyl)-4-oxo-3-phenyl-4 H -quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile with Improved Pharmacokinetic Profile and Superior Efficacy in Hematological Cancer Models.

Author

Shukla MR, Patra S, Verma M, Sadasivam G, Jana N, Mahangare SJ, Vidhate P, Lagad D, Tarage A, Cheemala M, Kulkarni C, Bhagwat S, Chaudhari VD, Sayyed M, Pachpute V, Phadtare R, Gole G, Phukan S, Sunkara B, Samant C, Shingare M, Naik A, Trivedi S, Marisetti AK, Reddy M, Gholve M, Mahajan N, Sabde S, Patil V, Modi D, Mehta M, Nigade P, Tamane K, Tota S, Goyal H, Volam H, Pawar S, Ahirrao P, Dinchhana L, Mallurwar S, Akarte A, Bokare A, Kanhere R, Reddy N, Koul S, Dandekar M, Singh M, Bernstein PR, Narasimham L, Bhonde M, Gundu J, Goel R, Kulkarni S, Sharma S, Kamboj RK, and Palle VP

Subjects
Animals, Antineoplastic Agents chemical synthesis, Antineoplastic Agents metabolism, Antineoplastic Agents pharmacokinetics, Cell Line, Tumor, Class I Phosphatidylinositol 3-Kinases chemical synthesis, Class I Phosphatidylinositol 3-Kinases metabolism, Class I Phosphatidylinositol 3-Kinases pharmacokinetics, Dogs, Drug Discovery, Female, Humans, Male, Mice, Mice, Inbred BALB C, Mice, Inbred NOD, Mice, SCID, Molecular Docking Simulation, Molecular Structure, Phosphoinositide-3 Kinase Inhibitors chemical synthesis, Phosphoinositide-3 Kinase Inhibitors metabolism, Phosphoinositide-3 Kinase Inhibitors pharmacokinetics, Quinolizines chemical synthesis, Quinolizines metabolism, Quinolizines pharmacokinetics, RAW 264.7 Cells, Rats, Sprague-Dawley, Structure-Activity Relationship, Xenograft Model Antitumor Assays, Antineoplastic Agents therapeutic use, Class I Phosphatidylinositol 3-Kinases therapeutic use, Hematologic Neoplasms drug therapy, Phosphoinositide-3 Kinase Inhibitors therapeutic use, Quinolizines therapeutic use
Abstract

PI3Kδ inhibitors have been approved for B-cell malignancies like CLL, small lymphocytic lymphoma, and so forth. However, currently available PI3Kδ inhibitors are nonoptimal, showing weakness against at least one of the several important properties: potency, isoform selectivity, and/or pharmacokinetic profile. To come up with a PI3Kδ inhibitor that overcomes all these deficiencies, a pharmacophoric expansion strategy was employed. Herein, we describe a systematic transformation of a "three-blade propeller" shaped lead, 2,3-disubstituted quinolizinone 11 , through a 1,2-disubstituted quinolizinone 20 to a novel "four-blade propeller" shaped 1,2,3-trisubstituted quinolizinone 34 . Compound 34 has excellent potency, isoform selectivity, metabolic stability across species, and exhibited a favorable pharmacokinetic profile. Compound 34 also demonstrated a differentiated efficacy profile in human germinal center B and activated B cell-DLBCL cell lines and xenograft models. Compound 34 qualifies for further evaluation as a candidate for monotherapy or in combination with other targeted agents in DLBCLs and other forms of iNHL.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results